RCUS (Arcus Bio) Likuiditas cepet

Arcus Biosciences, Inc. (RCUS) research and development capacities and biolabs are operating at full strength according to testing plans. This daily price chart for the company on the GURU.Markets platform currently shows a level of 4.00. The business relies on creating breakthrough oncology immunology treatments in collaboration with a market leader, minimizing costs through a major contract. Capital is formed via tranches from global pharma partners and future royalty payments.

Arcus Corp (RCUS) - Likuiditas kritis saka 04.07.2022 nganti 29.10.2026

arcusbio.com (RCUS) - rincian metrik lan laporan keuangan

- nilai pasar lan prakiraan target analis:

Bagan rega Arcus Bio|RCUS - Bagan rega target

- indikator valuasi pasar bisnis:

Nilai pasar Arcus Bio|RCUS - Total Nilai Perusahaan

- data kapitalisasi buku:

Nilai Buku saben Saham Arcus Biosciences|RCUS - Nilai Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih arcusbio.com|RCUS - Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

Rasio Total Utang marang Ekuitas Arcus Biosciences, Inc.|RCUS - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Arcus Biosciences|RCUS - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Arcus Bio|RCUS - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Arcus Biosciences|Indikator likuiditas cepet arcusbio.com

- indikator bathi lan kelipatan valuasi:

RCUS - Bathi resik

Analisis kabeh metrik perusahaan:Arcus Biosciences, Inc.

The development of innovative cancer immunotherapy and the partnership with Gilead Sciences require colossal expenditures, making the financial autonomy of Arcus Biosciences, Inc. (RCUS) critically important. Analyzing the significance of quick liquidity, the investor assesses the company's ability to settle short-term debts solely through cash and accounts receivable, ignoring less liquid inventories, which allows for the determination of the business's real margin of safety.

Pesaing utama